Показано 0 из 0
Дата |
---|
06.05.2024 |
03.05.2024 |
02.05.2024 |
01.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
1.39
|
1.85
|
1.70
|
1.675
|
1.75
|
1.70
|
|
|
493 985.55
|
1 289.00
|
1.39
|
1.85
|
1.77
|
1.68
|
1.79
|
1.70
|
|
|
802 067.29
|
1 705.00
|
1.40
|
1.78
|
1.67
|
1.62
|
1.69
|
1.65
|
|
|
788 029.95
|
1 911.00
|
1.46
|
1.73
|
1.46
|
1.44
|
1.61
|
1.57
|
|
|
425 921.02
|
1 642.00
|
1.39
|
1.56
|
1.45
|
1.41
|
1.47
|
1.44
|
|
|
148 299.47
|
521.00
|
1.41
|
1.61
|
1.47
|
1.40
|
1.50
|
1.46
|
|
|
119 436.18
|
709.00
|
1.39
|
1.59
|
1.51
|
1.40
|
1.51
|
1.45
|
|
|
95 517.19
|
419.00
|
1.41
|
1.57
|
1.42
|
1.33
|
1.48
|
1.48
|
|
|
706 335.83
|
2 452.00
|
1.20
|
2.28
|
1.56
|
1.44
|
1.59
|
1.48
|
|
|
223 657.72
|
861.00
|
1.20
|
2.28
|
1.49
|
1.48
|
1.56
|
1.52
|
|
|
109 523.81
|
521.00
|
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. immuno-oncology product candidates include a clinical-stage monoclonal antibody targeting solid tumors, a novel bispecific targeting PD-1 and PD-L1, and a portfolio of bispecific and monoclonal antibodies at various stages of pre-clinical development.